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REGULAR ARTICLE
Baseline and interim functional imaging with PET effectively risk
stratiﬁes patients with peripheral T-cell lymphoma
Neha Mehta-Shah,1,2,* Kimiteru Ito,3,* Kurt Bantilan,1 Alison J. Moskowitz,1 Craig Sauter,4 Steven M. Horwitz,1 and Heiko Scho¨der3
1Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; 2Division of Oncology, Department of Medicine, Washington University
in St. Louis, St. Louis, MO; and 3Molecular Imaging and Therapy Service, Department of Radiology, and 4Bone Marrow Transplant Service, Department of Medicine, Memorial
Sloan Kettering Cancer Center, New York, NY
Key Points
• In peripheral T-cell
lymphomas treated
upfront, baseline total
metabolic tumor
volume and interim
5-point score are
prognostic.
• Interim PET response
(assessed by 5-point
score) further risk
stratifies patients with
low and high baseline
clinical risk scores.
The prognosis of peripheral T-cell lymphoma (PTCL) is heterogenous. Baseline or interim
imaging characteristics may inform risk-adapted treatment paradigms. We identiﬁed 112
patients with PTCL who were consecutively treated with cyclophosphamide, doxorubicin,
vincristine, prednisone (CHOP)/CHOP-like regimens with the intent to consolidate with
an autologous transplant. Baseline (n 5 93) and interim (after 4 cycles, n 5 99) positron
emission tomography (PET) imageswere reevaluated, andwe calculated baseline totalmetabolic
tumor volume (TMTV). Interim PET (iPET) responses were graded visually by 5-point score (i5PS)
and by percentage change of standardized uptake value. By univariate analysis, predictors of
event-free survival (EFS) included Prognostic Index for Peripheral TCL (PIT) higher than 1
(hazard ratio [HR], 1.83; P 5 .021), International Prognostic Index (IPI) higher than 3 (HR, 2.01;
P 5 .021), high TMTV (.125 cm3; HR, 3.92; P 5 .003), and positive iPET (HR, 3.57; P , .001).
By multivariate analysis, high baseline TMTV predicted worse overall survival (OS; HR, 6.025;
P5 .022) and EFS (HR, 3.861; P 5 .005). Patients with i5PS of 1 to 3 had a longer median OS and
EFS (104 months, 64 months) than those with i5PS of 4 to 5 (19 months, 11 months; P , .001).
Four-year OS and EFS for patients with i5PS of 1 to 3 and PIT of 1 or less were 85% and 62%,
respectively. However, 4-year OS and EFS for those with i5PS of 4 to 5 and PIT higher than 1
were both 0% (P , .001). In multivariate analysis, after controlling for IPI and PIT, i5PS was
independently prognostic for EFS (HR, 3.400 95% conﬁdence interval, 1.750-6.750; P, .001) and
OS (HR, 10.243; 95% conﬁdence interval, 4.052-25.891; P , .001). In conjunction with clinical
parameters, iPET helps risk stratify patients with PTCL and could inform risk-adapted treatment
strategies. Prospective studies are needed to conﬁrm these ﬁndings.
Introduction
Peripheral T-cell lymphomas (PTCL) are heterogenous and rare lymphomas comprising approximately
10% of all non-Hodgkin lymphomas.1 This group of diseases is often associated with an aggressive
clinical course and relatively poor outcomes compared with their B-cell lymphoma counterparts.1,2
PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic TCL (AITL), and anaplastic lymphoma
kinase negative anaplastic large-cell lymphoma (ALK-ALCL) make up 25%, 19%, and 6% of PTCL with
5-year overall survival (OS) estimated at approximately 30% to 40%.1-3 Although there is no universally
accepted approach to treatment of these disorders, many centers initially treat fit patients with
cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)/CHOP-like regimens, often followed
by consolidation with an autologous stem cell transplant (ASCT) in first remission.4-6 With this strategy,
progression-free survival at 5 years is approximately 45%.4,7 Depth of remission at the time of transplant
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has been prognostic in PTCL, as well as other, aggressive
lymphomas.7-9 Therefore, it is hypothesized that the degree of
responsiveness to upfront chemotherapy is likely clinically important
when considering further treatment and consolidation strategies.
Although baseline clinical prognostic tools such as the International
Prognostic Index (IPI) and Prognostic Index for Peripheral TCL (PIT)
have helped risk stratify patients, but are not commonly used to
guide therapy.10,11 Interim response assessment may be helpful to
guide clinical decisions such as evaluating the benefit or necessity
of ASCT as consolidation of first remission compared with consider-
ation of an alternate strategy. Among patients who are not candidates
for an allogeneic transplant, the median OS in those with relapsed/
refractory disease is 6 months.12 Therefore, earlier identification of
patients who are likely to benefit from curative treatment approaches
is especially clinically relevant.
The utility of PET has been studied in patients with various TCLs.13-24 The
5-point score (5PS) using interim 18-fluordeoxyglucose (18F-FDG)
positron emission tomography (PET) has been adopted in the response
evaluation of many forms of aggressive lymphoma, including PTCL as
a determinant of response.15,25 The 5PS appears to be a promising
parameter for prognostic stratification in multiple lymphomas, including
Hodgkin lymphoma, diffuse large B-cell lymphoma, and NK/TCLs.8,9,14,26
Studies of interim PET evaluation in TCL have shown that 70% of cases
with PTCL show a favorable response with 5PS 1 to 3 on interim PET
during initial chemotherapy. However, those who had early clinical
progression would not be represented in these series, as their
progression occurred before times for interim evaluation.21,22 More
recently, the Response Evaluation Criteria in Lymphoma (RECIL) have
emphasized the combined assessment of morphologic and functional
changes on imaging studies to characterize response and predict patient
outcome.27 RECIL criteria have not previously been applied in TCLs.
Although the role of total metabolic tumor volume (TMTV) analysis
has been elucidated in Hodgkin lymphoma and diffuse large B-cell
lymphoma, there is little known about the prognostic utility of TMTV
in PTCL.8,28-30
In this retrospective study of consecutive and uniformly treated
patients, we characterized treatment response based on interim
5PS and measured TMTV to better understand the potential clinical
utility of these imaging parameters in PTCL. In particular, we sought
to risk-stratify patients according to their baseline PET characteristics
and interim response, thus setting the stage for future risk-adapted
protocols in this disease.
Methods
Patients
The institutional review board approved this retrospective study
and waived the informed consent requirement in accordance with
the Declaration of Helsinki; the study was compliant with Health
Insurance Portability and Accountability Act requirements. Through
the Memorial Sloan Kettering Cancer Center lymphoma database,
we identified patients who either were consecutively treated at our
center at the time of initial diagnosis or were seen at our center
during their initial therapy from 2001 to 2015 and met the following
criteria: age, 21 years or older; a confirmed histological diagnosis of
PTCL-NOS, AITL, or ALK-ALCL based on the Revised European
American Lymphoma Classification, World Health Organization
2003, or World Health Organization 2008 classifications (accord-
ing to the schema in use at the time of diagnosis); initial treatment
with CHOP or CHOEP (cyclophosphamide, doxorubicin, vincris-
tine, etoposide, prednisone) with intent to consolidate with autolo-
gous transplantation; and at least 6 months follow-up or an event
defined as relapse or death from any cause. Patients with ALK1
ALCL were excluded. In all cases, the diagnosis was confirmed by
hematopathology review at Memorial Sloan Kettering Cancer
Center. Clinical data collected included age, sex, histologic subtype
of TCL, stage, number of extranodal sites, sites of involvement
including bone marrow, level of lactate dehydrogenase, IPI score,
PIT score, death, and relapse.
18F-FDG PET/computed tomography protocol
PET/computed tomography (CT) images were collected at baseline, at
interim evaluation (after 4 cycles of CHOP-based therapy), and at end of
treatment (EOT) before clinical decisions for ASCT, according to our
institutional practice. Before injection of 18F-FDG, patients fasted for at
least 6 hours. If plasma glucose levels were lower than 200 mg/dL,
patients were injected IV with approximately 12 mCi radiotracer. After a
standard 60- to 90-minute uptake time, 18F-FDG PET/CT was
performed on various scanners (GE Discovery Series: VCT, ST, STE,
and 690). The subjects were scanned while in the supine position.
Cross-calibration between the dose-calibrator and the PET scanners
was routinely performed. Phantom studies were used to ensure that the
quantitative measure was exact and minimized standard reuptake value
(SUV) differences between scanners, generally within 10%. CT images
of the PET/CTwere used for attenuation correction of the PET scan. The
attenuation-corrected data were reconstructed using an ordered-subset
expectation maximization algorithm and displayed for review using
standard manufacture-supplied equipment (AdvantageWorkstation, GE
Healthcare).
Response assessments using FDG PET and CT
All PET/CT scans were reviewed by 2 board-certified nuclear medicine
physicians, and interim and EOT PET images were scored using the
5PS.31 Controversial cases and all score 3 and 4 cases were
discussed by these 2 physicians, and consensus was reached. The
reviewers finalized their scan interpretation based on CT and PET
imaging features and known normal distribution of FDG to account for
non-tumor-related FDG uptake. The PET scores were incorporated
into RECIL for treatment response classification.
Quantitative PET parameters were computed by a board-certified
nuclear medicine physician. Using PET-VCAR software ver.3.2
(AdvantageWorkstation, GE Healthcare) on dedicated workstations,
the reviewer delineated the volume of interests in each region so as to
obtain the SUVmax. Lesional MTV was defined as the region
enclosed by a 41% isocontour around maximum PET voxel of a
lesion. Contours of conglomerated masses or a series of connected
lymph nodes were delineated using a semiautomatic contouring
system on the software. This method used the 41% SUVmax
threshold, similar to previous studies.24,25,32,33 A volume of interest
was set around each lesion (node or organ involvement). The spleen
was considered to be involved if there was focal uptake or diffuse
uptake higher than 150% of the liver background.20 Bone marrow
involvement was considered in volume measurement only if there
was clear focal uptake higher than background. The TMTV for a
given patient represents the sum of all individual lesional MTVs.
Occasional adjustments of the 41% threshold were performed if
the PET volume clearly extended beyond the lesion as seen on
CT (a blooming artifact).
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We also analyzed quantitative changes between baseline and
follow-up PET by calculating percentage decrease in SUVmax
between baseline PET and interim PET (interim DSUV) in 80
patients. The cutoff value of interim DSUVmax was set at 273%
(after 4 cycles), derived from previous studies.21 In addition to
metabolic parameters, we also measured the sum of the longest
diameter (SLD) in target lesions. This was done using the CT
images (at most 3.75 mm thickness) from the PET/CT or from a
separately acquired CT scan covering the same field of view (from
neck to upper thigh) and performed with or without IV contrast. Up
to 3 target lesions were selected according to RECIL 2017.27
DSLD (baseline 2 interim) and DSLD (baseline 2 EOT) were
calculated as percentage change. Response to chemotherapy
was characterized based on DSLD in combination with PET
response as complete response (CR), partial response (PR),
stable disease (SD) including minor responses, or progressive
disease.
Statistical analysis
Sensitivity, specificity, and diagnostic accuracy of FDG PET and
CT parameters were calculated for diagnostic values. Median
and receiver operating characteristic (ROC) curves were used to
analyze imaging quantitative value to determine the cutoff point that
yielded the highest combined sensitivity and specificity. To compare
FDG PET and CT for prediction of outcome, patients were
dichotomized into a good-response group and a poor-response
group by conventional criteria.32 Important prognostic factors found
to be significant by univariate analysis (P , .05) were entered
simultaneously into a Cox multivariate regression analysis model.
Event-free survival (EFS) was defined as time from diagnosis until
progression, relapse, death from any cause, or last follow-up visit.
OS was defined as time from diagnosis until death from any cause
or last follow-up visit. EFS and OS were estimated by Kaplan-Meier
method and compared by the log-rank test. Surviving patients were
censored at last follow-up. Characteristics of the population were
compared between groups, using Fisher’s exact or x2 tests, as
appropriate. F coefficient was used to estimate covariant of
association between nominal data. P , .05 was considered
statistically significant. All analyses were performed using SPSS
24.0 (SPSS, Chicago, IL).
Results
Patient characteristics
One hundred twelve patients with PTCL who were treated with the
intent to pursue autologous transplant after CHOP-like chemother-
apy in the upfront setting were identified. Their median age was
60 years (range, 22-79 years). Of these 112 patients, 99 had
sufficient-quality interim PET/CT images for independent review.
Their histologies were PTCL-NOS (n 5 38), AITL (n 5 40), and
ALK- ALCL (n 5 21) (Table 1). In these 99 patients, the median
age of the cohort was 60 years, and 66 patients (67%) were male.
Of the 99 patients with available interim PET, 53 patients (54%)
had a PIT score of 0 to 1 and 46 patients (47%) had a PIT score of
2 to 4. In addition, 20 (20%), 61 (62%), and 18 (18%) had an IPI
score of 0 to 1, 2 to 3, and 4 to 5, respectively. Other clinical
parameters are summarized in Table 1. There were no significant
differences between the entire cohort (n 5 112) and the group
of patients undergoing interim PET (n 5 99; supplemental
Table 1).
Characterization of imaging findings
Baseline imaging. At baseline, all patients had FDG avid
lesions. The median baseline SUVmax was 13.52 (range, 1.75-51.02).
Baseline TMTV was calculated for 68 patients whose baseline
PET/CT scans were of sufficient quality (supplemental Figure 1). The
median TMTV was 188.6 cm3 (range, 2.49-1839.42 cm3). All patients
had at least 1 measurable target lesion on baseline CT. The median
SLDwas 32.68 cm (range, 1.57-171.67 cm). There was no significant
difference in survival based on the presence of extranodal involve-
ment with regard to EFS (P5 .368) or OS (P5 .353). There were no
differences in OS (P 5 .286) or EFS (P 5 .245) by histology. In
addition, the TMTVs of 3 histological subtypes were similar.
Table 1. Patient characteristics of the interim PET cohort (n 5 99)
Characteristics No. (%) Characteristics No. (%)
Age, y Treatment
#60 51 (52) CHOP/ICE 39 (39)
.60 48 (48) CHOEP 22 (22)
Sex EPOCH 1 (1)
Male 66 (67) CHOP 21 (21)
Female 33 (33) Other 16 (16)
Histology Transplant
PTCL-NOS 38 (38) Autologous 61 (62)
AITL 40 (40) Allogeneic 6 (6)
ALCL, ALK2 21 (21) None 32 (32)
Ann Arbor stage Interim PET by 5PS
I-II 13 (13) 1 and 2 78 (79)
III-IV 86 (87) 3 5 (5)
Performance status (ECOG) 4 and 5 16 (16)
0-1 71 (72) EOT PET by 5PS (n590)
2-3 27 (27) 1 and 2 68 (76)
NA 1 3 2 (2)
Bone marrow involvement 4 and 5 20 (22)
No 72 (73)
Yes 27 (27)
LDH
Normal 50 (51)
High 45 (45)
NA 4 (4)
IPI
0-1 20 (20)
2-3 61 (62)
4-5 18 (18)
PIT
0 17 (17)
1 36 (36)
2 25 (25)
3 16 (16)
4 5 (5)
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NA, not
available; NS, not significant.
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Interim imaging. At interim, after 4 cycles of chemotherapy,
84% (83/99) of patients had a 5PS of 1 to 3, and 16% (16/99) had
a 5PS of 4 or 5. (Table 1) Median SUVmax on interim PET had
declined to 1.15, corresponding to median percentage decline
(DSUV) by 292.6% (range, 2100% to 110.8%).
RECIL response at the interim could be calculated for 81 patients
(Figure 1). The median percentage decrease of the SLD (DSLD) at
interim was 259.7% (range, 2100% to 29.9%).
EOT imaging. At the EOT, 78% (70/90) of patients had a
5PS of 1 to 3, and 22% (20/90) had a 5PS of 4 or 5. According to
RECIL criteria, 52 of the 70 patients with 5PS of 1 to 3 were
classified as CR. In contrast, 19 of the 20 patients with 5PS of 4
or 5 were classified as SD (n 5 6) or PR (n 5 13); no patient
had progressive disease. Among those who had CR at the EOT
by REICL, 13 did not ultimately undergo an autologous transplant
because of comorbidities or patient choice. Of note, 9 patients with
an interim PET did not have an EOT evaluation, 7 had a PET with
insufficient imaging quality for review, and 2 progressed before their
EOT evaluation.
Patient outcome and identification of
prognostic groups
The median OS and EFS of the entire cohort were 93 and 36
months, respectively. The survival curves for the entire cohort and
patients undergoing interim PET showed no significant difference
(data not shown). Figure 2 shows theOS and EFS for the interim PET
cohort. At 4 years, OS and EFS of this cohort were 69% and 48%.
In univariate analysis, IPI higher than 3 was predictive of OS
(hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.023-
4.513; P 5 .043) and EFS (HR, 2.012; 95% CI, 1.112-3.641;
P 5 .021). PIT higher than 1 was also predictive of EFS (HR,
1.825; 95% CI, 1.094-3.043; P 5 .021) and showed a trend
toward being predictive of OS (HR, 1.663; 95%CI, 0.877-3.155;
P 5 .12)
Stable disease including minor response (SD) (n=4)
Partial response based on PET (Deauville 4 or 5) and CT (30% decrease) (PR) (n=9)
Complete response based on PET (Deauville 1-3) and CT (30% decrease) (CR) (n=66)
Complete response on CT (no target lesion) (CR) (n=2)
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Figure 1. Waterfall plot according to RECIL in interim
PET/CT (n 5 81).
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Figure 2. OS and EFS for the cohort (n = 99). OS (A) and EFS (B) curves in interim PET cohort.
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Baseline TMTV and prognosis. To identify subsets of
patients with different outcomes as early as possible, we first
assessed the prognostic value of baseline TMTV by dichotomizing
patients by the median TMTV, which was 188.6 cm3. In this analysis,
median TMTV proved prognostic for both OS and EFS. We applied
ROC analysis to derive the optimal cutoff point to separate patients
with better and poor prognosis.
The area under the curve for 4-year OS was 0.671 (95% CI, 0.53-
0.81; P5 .04), and for 4-year EFS it was 0.671 (95%CI, 0.54-0.80;
P 5 .014). For both endpoints, the optimal cutoff value was
125 cm3, yielding a combined sensitivity and specificity of 88% and
46% for survival at 4 years, and 81% and 56% for EFS at 4 years,
respectively (Figure 3). Low and high TMVT were defined by ROC
cutpoints as less than 125 cm3 vs at least 125 cm3. TMTV higher
than 125 cm3 was associated with worse OS (HR, 6.813; 95%
CI, 1.511-30.725; P 5 .013) and EFS (HR, 3.921; 95% CI,
1.579-97.36; P 5 .003).
Treatment responses on interim PET and prognosis.
We then evaluated the prognostic value of interim scan findings. In
univariate analysis, interim 5PS of 4 or 5 was predictive of worse OS
(HR, 11.025; 95% CI, 4.409-27.571; P , .001) and worse EFS
(HR, 3.573; 95%CI, 1.824-6.997; P, .001; Table 2). Patients with
5PS of 1 to 3 had a median OS and EFS of 104 and 64 months,
respectively (Figure 4). In contrast, those with 5PS of 4 or 5 had a
median OS and EFS of only 19 and 11 months, respectively. Further
analyses were performed evaluating the combined prognostic
significance of interim 5PS and PIT (Figure 4). By RECIL, patients
with complete remission at interim evaluation had superior OS (HR,
9.699; 95% CI, 3.539-26.578; P , .001) and EFS (HR, 3.187;
95% CI, 1.508-6.736; P 5 .002) (Table 2; Figure 5).
Patients with interim DSUVmax higher than 73% had a significantly
better EFS (HR, 7.076; 95% CI, 3.283-15.282; P , .001) and
OS (HR, 6.253; 95% CI, 2.320-16.857; P , .001) compared with
those with a DSUV of 73% or less (Table 2; supplemental Figure 3).
Regarding changes of nodal size at interim, the optimal cutoff point for
DSLD (as derived from ROC analysis) to predict EFS was 253.7%;
log-rank; P 5 .019).
Combining imaging and clinical factors to evaluate
prognosis. In multivariate analysis, patients with favorable interim
PET (5PS, 1-3) and PIT of 1 or less had a 4-year OS and EFS of
85% and 62% compared with those with unfavorable interim PET
(5PS, 4 or 5) and PIT higher than 1 (4-year OS and EFS both 0%).
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Figure 3. OS and EFS by TMTV. OS (A) and EFS (B) curves by median (188 cm3) TMTV. OS (C) and EFS (D) curves using a ROC cutoff (125 cm3) for TMTV.
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In a subanalysis by Kaplan-Meier log-ranked evaluation, we
confirmed that patients with a 5PS of 1 to 3 and PIT of 1 or less
had significantly better OS than patients with a 5PS of 1 to 3 and PIT
higher than 1 (P 5 .035; Figure 4; supplemental Figure 2). When
controlling for PIT, interim 5PS PET was independently prognostic of
EFS (HR, 3.441 95% CI, 1.730-6.684; P , .001) and OS (HR,
10.277; 95% CI, 4.073-25.931; P, .001). When controlling for IPI,
interim 5PS PET was independently prognostic of EFS (HR, 3.437
95% CI, 1.750-6.750; P , .001) and OS (HR, 10.616; 95% CI,
4.216-26.733; P , 001). Similarly, in a multivariate analysis, when
controlling for IPI and PIT, interim 5PS PET was independently
prognostic of EFS (HR, 3.400 95% CI, 1.750-6.750; P , .001) and
OS (HR, 10.243; 95% CI, 4.052-25.891; P , .001; Table 2).
Under the hypothesis that larger initial tumor burden and poor
response on interim PET probably identifies a patient group with
worst prognosis, we conducted further analysis looking at both
TMTV and interim PET. As shown in Figure 4, patients with low
baseline TMTV and interim PET 5PS of 1 to 3 had superior
outcome. In particular, patients with low TMTV and interim PET 5PS
of 1 to 3 had significantly better EFS and OS than patients with high
TMTV and interim PET 5PS of 1 to 3 (P 5 .018 and P 5 .023).
It was confirmed on multivariate analysis that TMTV higher than
125 cm3 and interim 5PS of 4 to 5 remained independently
predictive of OS and EFS (Table 2).
There was direct correlation (r 5 0.7; P , .001) between the
groups stratified by DSUVmax (decline of.73% vs decline#73%)
and groups stratified by interim 5PS (1-3 vs 4 or 5). Of note, use of
quantitative DSUV in combination with baseline TMTV was not
superior to using 5PS combined with TMTV in a multivariate
analysis. In a subanalysis by Kaplan Meier log rank analysis, we
confirmed that patients with low TMTV and DSUV (decline of
$73%) had significantly better EFS and OS than patients with high
Table 2. Univariate and multivariate analysis of factors predictive of survival in patients
Variable
OS EFS
HR 95% CI P HR 95% CI P
Univariate analysis
IPI
.3 2.148 1.023-4.513 .043 2.012 1.112-3.641 .021
#3 1 (reference) 1 (reference)
PIT
.1 1.663 0.877-3.155 .12 1.825 1.094-3.043 .021
#1 1 (reference) 1 (reference)
TMTV, cm3
.125 6.813 1.511-30.725 .013 3.921 1.579-9.736 .003
#125 1 (reference) 1 (reference)
Interim 5PS
4 or 5 11.025 4.409-27.571 ,.001 3.573 1.824-6.997 ,.001
1-3 1 (reference) 1 (reference)
Interim DSUV, %
.273 6.253 2.320-16.857 ,.001 7.076 3.283-15.252 ,.001
#273 1 (reference) 1 (reference)
Interim RECIL
PR or SD 9.699 3.539-26.578 ,.001 3.187 1.508-6.736 .002
CR 1 (reference) 1 (reference)
EOT 5PS
4 or 5 3.199 1.502-6.814 .003 3.315 1.808-6.076 ,.001
1-3 1 (reference) 1 (reference)
EOT RECIL
PR or SD 2.054 0.866-4.870 .102 3.101 1.603-6.000 .001
CR 1 (reference) 1 (reference)
Multivariate analyses
TMTV, cm3
.125 6.025 1.288-28.177 .022 3.861 1.499-9.943 .005
#125 1 (reference) 1 (reference)
Interim 5PS
4 or 5 6.506 1.715-24.687 .006 3.407 1.212-9.579 .020
1-3 1 (reference) 1 (reference)
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TMTV and DSUV (decline of ,73%; P 5 .012 and P 5 .014;
supplemental Figure 3).
Similarly, using RECIL response at interim did not add prognostic
value when compared with interim 5PS alone in a multivariate
analysis. This occurred because interim RECIL classification (CR vs
PR1SD) showed near complete correlation with classification by
interim 5PS (1-3 vs 4 or 5) alone.
In summary, univariate analysis showed interim treatment response
parameters (5PS, DSUV, and RECIL) as factors significantly
associated with EFS and OS (Table 2). In a multivariate analysis,
both interim 5PS and MTV were statistically significant factors
associated with EFS and OS. Interim 5PS was also a significant
predictor in the other models combining PIT or IPI (supplemental
Table 2).
A
C
E
B
D
F
100
80
5PS(1-3)
5PS(4 or 5)
p 0.001
60
40
20
0
0
83
16
51
6
29
0
15
0
7
0
2
0
0
0
Number at risk
5PS(1-3)
5PS(4or5)
24 48 72 96 120 144
Months
Ov
er
all
 su
rv
iva
l (
%
)
5PS(1-3)
5PS(4 or 5)
p 0.001
83
16
40
5
22
0
13
0
5
0
2
0
0
0
Number at risk
5PS(1-3)
5PS(4or5)
0 24 48 72 96 120 144
Months
100
80
60
40
20
0
Ev
en
t f
re
e 
su
rv
iva
l (
%
)
5PS(1-3) and low TMTV
5PS(1-3) and high TMTV
5PS(4 or 5)
p =0.002 p =0.017
22
31
8
12
13
3
6
5
0
3
1
0
1
0
0
0
0
0
Number at risk
5PS(1-3) and low TMTV
5PS(1-3) and high TMTV
5PS(4 or 5)
0 24 48 72 96 120
Months
100
80
60
40
20
0
Ov
er
all
 su
rv
iva
l (
%
)
5PS(4 or 5)
Months
5PS(1-3) and low TMTV
5PS(1-3) and high TMTV
22
31
8
10
10
2
5
3
0
3
0
0
1
0
0
0
0
0
Number at risk
5PS(1-3) and low TMTV
5PS(1-3) and high TMTV
5PS(4 or 5)
0 24 48 72 96 120
100
80
60
40
20
0
Ev
en
t f
re
e 
su
rv
iva
l (
%
)
PIT1 and 5PS(1-3)
PIT1 and 5PS(4or5)
PIT1 and 5PS(1-3)
p 0.001
47
36
7
9
34
17
3
3
19
10
0
0
11
4
0
0
5
2
0
0
1
1
0
0
0
0
0
0
Number at risk
PIT1 and 5PS(1-3)
PIT1 and 5PS(1-3)
PIT1 and 5PS(4or5)
PIT1 and 5PS(4or5)
0 24 48 72 96 120 144
Months
100
80
60
40
20
0
Ov
er
all
 su
rv
iva
l (
%
)
PIT1 and
5PS(4or5)
PIT1 and 5PS(1-3)
PIT1 and
5PS(4or5)
PIT1 and 5PS(1-3)
p 0.001
47
36
7
9
27
13
3
2
16
6
0
0
10
3
0
0
4
1
0
0
1
1
0
0
0
0
0
0
Number at risk
PIT1 and 5PS(1-3)
PIT1 and 5PS(1-3)
PIT1 and 5PS(4or5)
PIT1 and 5PS(4or5)
0 24 48 72 96 120 144
Months
100
80
60
40
20
0
Ev
en
t f
re
e 
su
rv
iva
l (
%
)
PIT1 and
5PS(4or5)
Figure 4. Combining interim PET with clinical risk factors. OS (A) and EFS (B) curves by interim 5PS alone. OS (C) and EFS (D) curves of combined 5PS with PIT.
OS (E) and EFS (F) curves of combined 5PS with metabolic tumor volume (TMTV).
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Treatment responses at EOT. EOT PET using the 5PS
predicted both EFS (P , .001) and OS (P 5 .001) (supplemental
Figure 4). Considering PIT or IPI in addition to EOT PET did not
improve the prediction of patient outcome on multivariate analysis.
Discussion
We present the results of a retrospective study of consecutive,
uniformly treated patients with the more common forms of PTCL
(excluding ALK1 ALCL) to evaluate the prognostic value of interim
PET by 5PS, as well as TMTV and DSUV. We sought to examine
whether these functional imaging parameters added to commonly
used clinical risk stratification scores such as PIT and IPI.
This retrospective study generated several important findings: First,
we showed that the PET parameter baseline TMTV has prognostic
value in PTCL, alone or in combination with clinical indices. We
further demonstrated that interim PET using the 5PS can further
discriminate groups of patients with variable prognosis independent
of clinical prognostic indices such as PIT and IPI. Moreover, TMTV in
combination with interim imaging data (using 5PS, DSUV, or interim
RECIL response) was able to stratify the patients and identify a
group of patients with PTCL with much better outcome.
Previous studies have evaluated the role of interim PET/CT in TCLs
before the adoption of the 5PS system. Major studies performed
before the use of the 5PS system showed that patients with
negative interim PET achieved an approximately 70% PFS at 3 to
4 years compared with only 20% to 30% among patients with
positive interim scan.16,21 In comparison, in our series using the
5PS, the 4-year EFS in patients with negative interim PET was
58%, and patients with positive interim PET had a 4-year EFS of
0%. Furthermore, we demonstrated that the interim PET helped to
better stratify patients with low or high PIT.
Accordingly, overall, the 5PS helped to risk-stratify patients with
PTCL who were treated with a uniform approach of induction
chemotherapy followed by an intent to consolidate with ASCT. Of
course, our findings do not pertain to patients with progressive
disease before their interim evaluation, which may explain some
of the differences in outcomes for our cohort compared with
published registry studies. In a previously published study from our
group that evaluated patients (2001-2011) treated with the intent
to transplant, we identified that 12% of patients had disease
progression by the time of their interim scan. This study does not
address whether interim PET should be performed at an earlier time.
We know of at least 1 prospective study that will provide data
regarding interim PET at an earlier time (NCT 02561273).
We further showed that baseline TMTV carries prognostic in-
formation among patients with PTCL. In this series, TMTV of
125 cm3 was identified as the best threshold to separate patients
with good from those with poor prognosis. Although several studies
have shown that patients with high initial metabolic tumor burden
have generally worse outcomes, the optimal method to derive TMTV
and the reproducibility of the method are still the subject of ongo-
ing investigations. The methods currently being tested vary in their
way to calculate volumes.33 In addition, the optimal cutoff value to
segregate patients with good from those with poor prognosis
depends on the characteristics of the study population. In a similar
retrospective study, Cottereau et al recently published their analysis
of interim PET and TMTV in 140 patients with PTCLs, includ-
ing those who were not treated with the intent to transplant in
first remission and those with ALK1 ALCL.20,21 The researchers
demonstrated that baseline TMTV of 230 cm3 or less risk-stratified
patients with PTCL.21 Although their results also demonstrate that
interim PET and TMTV can help in stratifying patients with PTCL,
16% of patients in their series had ALK1 ALCL, which is a more
chemosensitive disease with favorable prognosis.20,21 In the previous
studies of PTCL, TMTV classified patients with unfavorable prognosis
defined as combined with 5PS or PIT into subgroups with very poor
prognosis.20,21 Conversely, TMTV in our study was able to further
classify patients with favorable prognosis defined as combination of
interim 5PS (or interim DSUV) into subgroups with excellent and
poor prognostic groups. These differences of stratifications might
depend on the difference of the optimal TMTV cutoff and study
population. Nevertheless, both studies demonstrate that patients
with PTCL with high tumor burden are at higher risk for treatment
failure and have generally shorter survival than those with low tumor
burden. Therefore, we believe that baseline TMTV, as an independent
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Figure 5. Survival by interim RECIL. OS (A) and EFS (B) curves by interim RECIL.
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prognostic factor, has a potential ability to extract a patient
population with excellent outcome. Whether these most favorable
patients could fare just as well with a less intensive approach than
that given here could be the subject of a future study. However,
we would point out that no constellation of favorable baseline
characteristics (low TMTV and low PIT) could identify a group with a
5-year EFS higher than 70%. Furthermore, the added value of 5PS
in patients with high or low TMTV could not be addressed in our
analysis.
Of note, although some prognostic information can already be
obtained from baseline PET and clinical parameters before
initiation of therapy, more accurate stratification can happen
at the time of interim assessment, using the interim 5PS alone or
in combination with clinical parameters (Figure 5). Although
interim DSUV also stratified patients with good vs poor outcome
(supplemental Figure 3), this more quantitative approach did
not provide any additional information beyond that available
from the widely established 5PS alone. As calculation of DSUV
is technically more challenging, we favor the use of 5PS for
interim prognostic evaluation. In addition to metabolic response,
morphological response on CT images is incorporated into
response criteria such as Lugano classification and RECIL. The
objective of RECIL is to simplify response assessment and to
characterize suboptimal response in greater detail. In the
current study, RECIL could be applied, but it did not provide
better risk stratification than PET alone, largely as a result of
complete concordance with the 5PS. Favorable RECIL re-
sponse corresponded with the presence of complete remission
on interim PET by 5PS, and both are markers of responsiveness
to chemotherapy.
In an era of precision medicine biomarker-driven treatment
algorithms, there has been an emphasis on response assess-
ment using modern imaging studies in lymphoma. Current
prognostic indices primarily rely on clinical factors. However,
our study demonstrates that PET response to therapy is a key
component of prognostic stratification. Patients with interim
5PS of 4 or 5 had uniformly poor outcome; no patient survived
beyond 4 years. In contrast, patients with favorable interim
5PS had significantly better outcomes, even when considered
to be at high risk based on baseline PIT. These data are in
concordance with prior studies demonstrating generally poor
outcomes for patients not achieving response to upfront
chemotherapy.1,3,7 Accordingly, because outcomes are gener-
ally poor for patients with interim 5PS of 4 or 5, it would seem
reasonable to change their chemotherapy regimen and consider
consolidation with allogeneic transplant if remission is achieved.
Identifying this especially high-risk subgroup serves as evidence
that this population warrants further study; this population could
be targeted for novel therapeutic approaches in clinical trials.
Most clinical trials in relapsed/refractory TCLs have not had
predefined subgroup analysis. For instance, one may consider
further studies to evaluate a PET adaptive approach to consid-
ering consolidation with ASCT in CR1. Alternatively, interim PET
evaluation could allow earlier identification of patients in whom this
strategy is destined to fail, directing them to other approaches
such as clinical trials of nonchemotherapeutic agents and/or
allogeneic stem cell transplantation. It is important to note that all
subjects included in our analysis were treated with the intent to
proceed to ASCT in CR1. Therefore, our study does not address
the need for, or added benefit of, consolidation. However, our data
also could serve as background to a study seeking to identify
subjects with favorable prognosis without consolidation.
The usual limitations of retrospective analysis apply to our study.
In our study, only 16 patients had an interim 5PS of 4 to 5. In
other studies, the rate of interim PET positivity was higher. However
those studies included a more heterogeneous patient population
(including ALK1 ALCL) and were not treated uniformly.21,22 All
patients in this series were treated uniformly with the intent to
transplant in first remission, and the overall response rate to CHOP-
based therapy was similar to other prospective series.4 Our results
may not be able to be extrapolated to patients who are not treated
with that approach. Only 5 patients had an interim 5PS of 3, leading
to uncertainty of whether patients with 5PS 3 can indeed by lumped
together with those with 5PS 1 or 2 in PTCL. As our series had a
long observation period of 15 years, technological developments of
PET scanners and software may have affected SUV and TMTV
measurements. However, this change in technology would not be
expected to influence 5PS, which is a relative score, based on
comparison of tumor FDG uptake with normal activity in reference
regions within the same scan. Similarly, although modern PET
scanners often yield higher SUV numbers for a given lesion (related
to improved scanner performance and image reconstruction),
calculation of DSUV is likely not affected by this, as baseline and
follow-up scans are performed within a few months, and thus on the
same generation of equipment.
In conclusion, baseline TMTV and at interim 5PS are both
independent prognostic factors in patients with PTCL. In this
series, the use of interim 5PS in PTCL was independently predictive
of outcome when controlling for clinical risk scores such as PIT and
IPI. Interim PET evaluation also identified a particularly high-risk
group that may benefit from alternative treatment strategies earlier
in the treatment course. This information may help to develop more
individualized treatment strategies for patients with PTCL with
varying prognosis, as well as aid in the design and interpretation of
clinical trials in the future.
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